28% GROWTH IN FIRST QUARTER

FIRST QUARTER 2012

  · NET SALES amounted to MSEK 30.6 (23.9).
  · OPERATING
PROFIT totalled MSEK 8.5 (6.8).
  · PROFIT AFTER TAX amounted to MSEK 6.4
(5.1).
  · PROFIT AFTER TAX PER SHARE was 0.71 SEK (0.55).
  · TOTAL CASH FLOW
was MSEK 9.7 (-4.7).

SIGNIFICANT EVENTS DURING THE FIRST QUARTER:

  ·
Probi signed a distribution agreement with USV Limited of India pertaining to
the launch of stomach capsules based on ProbiDigestis, Probi’s product platform
for gastrointestinal health.
  · Income in Functional Food increased 6% to MSEK
16.6 (15.7).
  · Income in Consumer Healthcare increased 73% to MSEK 14.4
(8.3).

SIGNIFICANT EVENTS AFTER THE CLOSE OF THE PERIOD:

  · Probi signed
an agreement with H.J. Heinz of Australia for the launch of probiotic juice
based on ProbiDefendum, Probi’s product platform for the immune system.

CEO’S
COMMENTS:

“Q1 income of slightly more than MSEK 30 represents the highest
level to date in a single quarter. Our continued strong growth in Consumer
Healthcare demonstrates that our strategy to focus resources on developing this
market is correct. Our new agreement in the major and expanding Indian market
will generate additional opportunities. Combined with this, we are focusing on
strengthening our organisation to cope with continued international expansion.
We are also very proud of our agreement with Heinz, entailing the launch of a
completely new product category in the Australian juice market,” says Michael
Oredsson, CEO of Probi.

This type of information is such that Probi AB must
disclose in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. The information was submitted for publication
on 26 April 2012 at 11:30 a.m.

This is a translation of the Swedish version
of the interim report. When in doubt, the Swedish wording prevails.
FOR FURTHER INFORMATION, PLEASE CONTACT:

Michael Oredsson, CEO of Probi, tel:
+46 (0)46-286 89 23 or +46 (0)707-18 89 30
e-mail: michael.oredsson@probi.se
ABOUT PROBI

Probi is a leading player in probiotic research and development
of effective and well-documented probiotics. The research areas are: the
gastrointestinal tract, immune system, metabolic synddrome, as well as stress
and recovery. Probi’s customers are leading companies in the Functional Food and
Consumer Healthcare segments. Total income for 2011 was MSEK 95.0. Probi’s share
is listed on Nasdaq OMX Stockholm, Small Cap. Probi has approximately 4,500
shareholders, Read more on www.probi.se.
28% GROWTH IN FIRST QUARTER

Attachments
